GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges : Episode 4
Patient Subgroup Outcomes with GPRC5D Bispecifics
Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.
- Have any patient subgroups demonstrated notably different outcomes with these GPRC5D bispecific therapies?
Recent Videos
Related Content
